INTRODUCTION
The potential of the genetic association approach for the identification of genetic variants that alter susceptibility to common complex disease is well recognised. 1 This potential equally extends to the identification of genetic variants in genes coding drug-metabolising enzymes, transporters, receptors, and other drug targets that may determine inter-individual differences in drug responsiveness or the frequency of adverse drug reactions. Technological advances such as the availability of single nucleotide polymorphism (SNP) databases and affordable, very high throughput genotyping are set to extend the potential and improve the efficiency of association approaches. However, the very large number of genetic variants in the human genome 2 and the lack of detailed knowledge about the molecular and biochemical processes involved in aetiology of complex diseases or in drug response suggest that it is very likely that many spurious associations will be found and reported. The great majority of reported associations have not led to new insights into complex disease or drug response mechanisms. Important exceptions include genetic variants whose effects are large enough to be identified by linkage analysis (eg), variants in NOD2 in Crohn's disease, 3 APOE in Alzheimer's disease 4 and factor V Leiden in deep venous thrombosis 5 ) and genetic variants in the cytochrome P450 CYP3A5 gene, which contribute to variation in bioavailability and clearance of drugs such as HIV protease inhibitors and some cholesterol-lowering drugs, and can result in drug toxicity. 6 The primary aim of these studies is to identify significant associations between genetic variants and disease states, physiological or disease traits or markers of drug response or toxicity and then to judge whether these associations are 'causal' (truly alter susceptibility to disease or drug response). However, deciding which statistically significant associations are indeed causal is likely to represent a major obstacle to successful 'gene discovery', at least until the time when molecular pathways from gene to disease become better understood. In this review we discuss the correct use and limitations of existing criteria for the interpretation of association studies.
INTERPRETATION OF GENETIC ASSOCIATION STUDIES
In the most commonly employed (inductive) approach an assessment is first made of the validity of the observed association between the genetic variant and the disease or trait (statistical inference). This involves considering the likelihood that alternative explanations of chance, bias and confounding could account for the findings. Secondly, all available biological and epidemiological evidence should be assessed to decide if the association is likely to be causal (causal inference). This judgement is essential in order to decide what action is merited based on the results: guiding prioritisation of investment in future research, clinical management decisions or public health policy choices. This approach is one of inductive inference (which involves judging whether there is support for inferring a casual association based on the observed data).
STATISTICAL INFERENCE
Chance, bias and confounding are all alternative explanations for observed associations (Table 1) .
Chance A statistically significant result does not mean that chance cannot have accounted for the result, only that this is unlikely. It is a composite measure that reflects both the size of the difference and the sample size. Statistical significance testing does not give a yes/no answer but acts as a guide to whether the hypothesis or reported association is likely to be worthwhile pursuing further. 7 Multiple testing is a major reason for published false positive reports. The expected frequency of false positives is given by 1À(1Àk) m (where m is the number of independent markers and k is usually o0.05, the significance level set for a single marker). 8 Reporting results of secondary and post hoc subgroup analyses as if they related to a priori hypotheses and selectively reporting only analyses that reach 'statistical significance' lead to covert multiple testing. New developments such as massive candidate gene analysis, genome screening by genetic association and adoption of pattern recognition methods such as artificial neural networks 9 will exacerbate the problem of multiple testing. Adopting statistical significance levels appropriate to the number of tests carried out can be used to limit the reporting of chance findings. In genetic linkage analysis of Mendelian traits, the adoption of the LOD score threshold of 3 or more has been effective in reducing the number of false positive reports to below 5%. 11 Unfortunately, there is no similar international consensus for the interpretation of genetic association studies. [12] [13] [14] The Bonneferoni correction for multiple testing assumes that all variants being tested have equal prior probability and takes no account of the dependence that exists between adjacent variants. It thus leads to overcorrection, risking rejection of important findings. Schork has proposed a method to estimate the probability distribution of genetic association (case-control) test statistics empirically so that significance of genetic variants being studied can be assessed against this distribution. This method, however, is likely to be population and genome region specific. 15 An alternative strategy would involve grouping the variants to be tested into groups with differing prior probabilities (eg, variants with known effects on protein function would have higher prior probability) and applying empirical Bayes or semi-Bayes adjustments. 16 , 17 Greenland has noted that such a Bayesian analysis leads to a modest loss of power but a 'dramatic reduction in type 1 (false positive) errory by the use of prior information'. 18 As the functional significance of variants is better understood, so it will be increasingly possible to adopt an informed approach to adjustment of significance levels. 16 This principle is similar to the practice in clinical genetic risk counselling in which the significance of genetic variants is interpreted through the use of other relevant genetic information. 19 Statistical tests of association are not strictly valid when there is dependence between individuals due to cryptic relatedness, which may or may not be apparent in recently collected pedigree data. This will lead to false positive associations particularly in inbred populations and in studies of rare disorders unless statistical methods that detect and account for these relationships are used. [20] [21] [22] Bias Any systematic differences in allele frequencies between cases and controls can result in an apparent association. Sources of bias (for example in the selection of study population or measurement of variables in cases and controls) have been discussed in detail. [23] [24] [25] In general, study designs that are prospective and in which case and control ascertainment is truly population based are more robust. The presence of artefacts leading to information bias can be explored by checking that genotype frequencies among controls are in Hardy-Weinberg equilibrium. Failure to find this draws attention to a problem with the selection, storage or analysis of control specimens and may suggest invalidation of the results of the association study.
Publication bias leads to the publication of relatively small initial studies selectively reporting large effects since they do not have adequate power to identify smaller effects. Studies reporting smaller effects do not reach statistical significance and so remain unpublished. 26 Subsequent more powerful and often better designed studies report more valid findings that either fail to reproduce the initial report (which then represent a false positive report due to a combination of chance and publication bias) or support the initial findings but with a more accurate (and modest) effect size. 27, 28 Confounding Confounding factors are those that are associated with both the disease and the factor under study. Thus an apparent association between a genetic variant and a disease or drug reaction may be explained by confounding. 24 The size of the effect of a confounding factor is related jointly to its association with the factor under study and to the outcome. Multiple factors can contribute small amounts of confounding that together are substantial. 29 Strategies to control for confounding are limited since they can only be applied to factors that are currently known.
Most discussions of confounding in genetic association studies have focussed on population stratification although examples of its importance are few. 30 Biologically, plausible levels of population stratification are likely only to result in weak associations. 31, 32 Approaches to limit or control population stratification include the use of family-based controls. However, the advantages of this approach have to 21, 33 These can be incorporated readily into studies of multiple candidate variants and are likely to be increasingly adopted.
Linkage disequilibrium (LD) between a (marker) variant under study and the true disease-susceptibility variant can result in confounding. High levels of LD within a population will increase the potential for confounding. Thus, although it has been proposed that initial association (LD mapping) studies be undertaken in small founderpool populations with extended LD, confounding will complicate interpretation of findings. In addition to concerns about the irregular fine structure of LD, 2 frequent gene conversion disrupting regions of LD and the complex relationship between genetic and physical distance, 34, 35 all positive associations will need to be followed by investigation of association in nearby variants and in surrounding haplotypes. 36 Fine mapping, for example by multiple candidate allele association analysis, will be more efficient in populations with low levels of LD, such as found in African populations. 37 High levels of LD (and thus confounding) within a population are likely to be regarded increasingly as a negative rather than a positive population attribute for genetic association studies.
CAUSAL INFERENCE
If chance, bias and confounding are all considered to be unlikely explanations for an observed association (Table 2) then it can be considered valid. A systematic approach to assessing whether valid associations may be causal can then be employed. Such approaches cannot prove causality since inference of cause from empirical data has no logical basis. 38 In addition, the aetiological heterogeneity and multifactorial nature of common complex disease, in which most factors under study will individually be neither necessary nor sufficient to cause the disease, complicates any approach to assessment of cause and effect relationships. Nevertheless, a set of criteria proposed by Bradford-Hill 39 based on the inductive canons of John Stuart Mill have proven useful (Table 3 ) and the utility of these are discussed below.
Consistency of Association
This approach parallels the successful strategy in linkage analysis whereby initial reports (with LOD score 43) need to be corroborated by an independent study to ensure a sound basis for genetic risk calculations. 40 In the absence of a broader understanding of genetic effects at the molecular level and of biochemical and physiological mechanisms, this criterion might seem the most powerful evidence in favour of causality currently available.
Replication of an association in the same population either in a 'split sample' or repeat independent sample gives evidence in favour of the variant being a causal variant. However, repeatability (probability that a second association study is also positive in the same population) varies with sample size and the proportion of trait variance attributable to the variant under study. Simulation has shown repeatability to be low with sample sizes of Table 2 Appraisal of published associations with genetic variants: list of questions to consider in assessing validity of association Chance * Is it clear whether reported results relate to a priori hypotheses or post hoc subgroup analyses? * Is the total number of analyses (number of tests) that were carried out stated? * Has an adjustment of the statistical significance level to account for multiple tests (eg), Bonneferoni or Bayes methods) been made or has interpretation of results otherwise accounted for multiple testing? * Does statistical analysis account for increased likelihood of chance association in inbred populations or, where relevant, due to cryptic relatedness in apparently outbred populations? * Where no statistically significant association was found, was the sample size large enough for adequate (eg, 80%) power to detect important/plausible effect sizes? Bias * Were the genotype frequencies reported in the control specimens in Hardy-Weinberg equilibrium? If this was not the case, were the reasons for this explored? Could this signal the presence of bias or study artefacts? * Are the procedures for the ascertainment of cases and controls carefully described; could they have resulted in bias that could explain the results? * Is the control group drawn from the same population as the cases? * If 'convenience' controls were used (such as blood donors) is information presented on the degree to which they are representative of the population from which the cases are drawn? Could these differences explain the results? * If published control allele frequencies were used to give control data, was their appropriateness in this study population reviewed critically? 100-500 cases 41 and empirical data confirm this with studies of sample size less than 150 followed much more often by studies reporting discrepant results. 27 Seeking replication of an association in another population is only valid if it is likely that the two data sets share the same measurement value (within sampling variability). 40 Substantial between-study heterogeneity has been clearly shown in a review of repeated genetic association studies. 27 Thus, the prospects for replication are uncertain when the validation sample differs genetically and/or environmentally from the original study population. 42 Different proband ascertainment strategies, multiple disease alleles, outbreeding and environmental modifiers all act to make replication of findings less likely. 40 Where LD is the basis of the observed association, this is not likely to be consistent across populations since LD depends on population history. Even when the 'causal' disease susceptibility variant is under investigation, a genetic variant may be more or less important in different populations depending, for example, on population allele frequencies. It may prove particularly problematic to replicate associations reported in 'special' populations (genetic isolate, admixed or those with unusual environmental exposure patterns) especially if the variant studied has low relative risk, variable penetrance and very variable allele frequencies in different populations. More generally, rare variants (o5% population prevalence), which may be particularly important in the aetiology of complex disease, 43, 44 are more likely to be population-specific. Replication in another population of associations with rare variants may not be possible. 45 In these circumstances other alternative (functional) variants in the gene under investigation should be studied. Positive associations with these variants could represent evidence in favour of a causal role. This is similar to finding family specific mutations in linkage studies of a Mendelian disease. Risch has suggested that such allelic heterogeneity provides strong evidence of a causal relationship. 10 Replication studies must therefore ensure they have a sufficiently large sample size to give adequate power to detect the association (see also tendency to over-estimate effect sizes and hence study power 42 below). Due to the problems with replication in other populations, integrated study designs 46 that permit an internal check in an independent sample of the same population should be favoured. This could include, for example, designs that include cases and both population-and family-based controls. Repetition by a transmission disequilibrium test (TDT) study following a reported association in a case-control study demonstrates both linkage and association and would further strengthen the evidence for a causal association.
When an association is confirmed in other populations then chance is a highly unlikely explanation. However, failure to confirm the association is more problematic to interpret, as discussed above. Rejection of findings not replicated in other populations may discard genetic effects with important effects specific to population subgroups.
Strength of Association
In complex causal pathways with multiple interacting causes (none of which might be either necessary or sufficient), associations tend to be of modest strength and inferences based on the relative strength of individual estimates of relative risk are problematic. Added to this, the application of this criterion in judging whether an association may be causal is complicated by a number of factors which bias reports of association strength. A consistent upward bias in published estimates of locus-specific effect sizes has been noted. This is due to publication bias in initial reports 27 and also due to the 'Beavis effect', particularly when maximum likelihood methods are employed. 42 In LD mapping studies the strength of association is influenced by the extent of LD between and the relative frequencies of marker and susceptibility variants. Thus, strong associations may be reported for a marker in strong LD with 47 
Biological Plausibility
The molecular nature of the genetic variant may guide interpretation of an observed association with a disease, disease trait or adverse drug reaction (Table 4) . Where appropriate, the adoption of an underlying biological model (for example, the multistep model of carcinogenesis) may provide a useful framework for interpretation. As the function of specific genes and their role in biological processes become better understood, it will be increasingly possible to direct 'candidate gene' studies based on this knowledge. This Bayesian approach would favour investment in (persisting with) investigation of variants in which there are prior biological reasons to suspect a role for a candidate gene (Table 4) . For example, genes that are more highly expressed (high number of mRNA copies) in tissues in which disease pathology is known to occur could be selected first for study. 48 This has been shown to result in a 30 to 100-fold reduction in the number of genes to be screened. 49 It is likely to be more efficient to investigate SNPs in coding and promoter regions or SNPs that define 'haplotype tags' 50 than random SNPs. Typologies of SNPs similar to the classification system in Table 4 have been developed. 10, 51, 52 Critical biochemical processes that are well defined and under the control of both genes and environmental exposures might prove to be good starting points for the investigation of the role of genetic factors in pathogenetic mechanisms.
Current approaches to the assessment of biological plausibility are subjective and unsatisfactory. They are typically based on prior beliefs or involve post hoc biological hypotheses being drawn up by investigators keen to find support for an observed association.
Emerging bioinformatics methods in biological sequence comparison, computational gene prediction, identification of functional gene signals and prediction of protein structure 53 should allow Bayesian methods to quantify 'biological plausibility' on a probability scale. This will permit biological plausibility to be assessed objectively in a scientific manner and will greatly improve the utility of this criterion in causal inference.
Biologic Gradient (Dose-Response Relationship)
The presence of a gradient supports the interpretation that the variant truly alters susceptibility to disease, although association due to confounding factors can also show a gradient. However, the presence of a gradient is dependent on the underlying genetic model. Thus, if there is a moderate risk of disease in heterozygotes and (very) high risk in homozygotes, this not only favours causal association but provides information on the underlying model (in this case recessive). Conversely, interpretation of results is complicated by lack of knowledge of the particular underlying genetic model that is operating and so lack of a gradient is not necessarily evidence against causal association. A threshold effect may be seen in which no effect is observed until there is a certain level of 'exposure' F with genetic factors this may be through multiple Table 4 Examples of the synthesis of epidemiological and biological data in the design or interpretation of genetic association studies
Study Design
Use of both epidemiological and biological data to define criteria for selection of candidate genes Strong justification: * Genetic variant associated with familial forms of disease * Genetic variant in exon or intronic promoter region of gene coding for proteins involved in molecular mechanisms of disease or for xenobiotic enzymes thought to interact with environmental exposures known to mediate risk of disease * High mRNA copy number in tissues affected by pathological process Weak justification: * Genetic variant found to be associated with disease risk in other published reports but no other supporting biological data Use of data from genetic association studies to direct functional investigation of candidate genes ('statistical functional genomics') 57 * Enumeration of all genetic variants in a genomic region * Results of genetic epidemiological analysis direct and prioritise subsequent molecular and functional studies Data analysis/interpretation Use of biological criteria to classify genetic variants into categories with differing probabilities of having a true pathological role: susceptibility variants interacting to disturb homeostatic mechanisms and thus alter a trait value.
Temporal Relationship
This criterion is apparently self-evident in genetic studies since the genotype is fixed from conception and thus always precedes disease or drug response. However, consideration of this criterion may be relevant in the study of epigenetic changes such as methylation of DNA or DNA adducts (from carcinogens, which can occur in response to environmental exposures later in life) or in gene expression studies (with genes up and down regulated). Evidence that specific epigenetic changes occurred before the earliest pathological changes would be consistent with an interpretation that they may have caused the changes.
Specificity
Genetic variants are likely to have pleiotropic effects and thus would not be expected to show highly specific pathological effects. However, this criterion may be helpful in a broader sense, for example, if there is a large pedigree or an unusual (isolate or admixed) population in which a specific subtype of a complex disease is found. This may be represented as an extreme incidence or prevalence of disease or as very early onset disease or very severe disease. If related pathophysiological and biochemical evidence confirms a specific subtype of the complex disease then populationor pedigree-specific variants may lead to very specific forms of disease and this may provide evidence in favour of causality.
Analogy This is the weakest criterion, as analogies can be readily found everywhere. Test of causal hypotheses. A list of competing explanations (or hypotheses) for the association is set out. These can be found in the columns (eg, chance, population stratification, linkage disequilibrium with causal variant or causal association with the variant showing association). It is assumed by deduction that one of these is correct.
The competing explanations are then tested against the observed data by considering the criteria listed in the rows. If only one remains unrefuted then it is considered to be correct. The comments in the table against/in favour represent evidence against/in favour of this interpretation; and against/in favour represent strong evidence against/in favour of this interpretation. This is similar to an outbreak investigation in that possible exposures that may have caused the outbreak are eliminated one by one (eliminative induction).
38
a Assuming that there is a sufficient sample size to assure good probability of repeatability of true finding. b Evidence against this interpretation if replication study used different study design (for example family-based controls in repeat study if original used population-based controls).
c Evidence against this interpretation if replication study used family-based controls. d Definition of 'strong' association in a complex disease will vary: an unbiased odds ratio of greater than 2 is strongly against an interpretation of population stratification; an unbiased odds ratio of greater than 3-5 is strongly in favour of a causal variant.
e Assuming subjective assessment of biological plausibility; evidence in favour/against is stronger if objective quantified assessment of biological plausibility is made.
Genetic association studies in complex disease
H Campbell and I Rudan
EXPERIMENTAL EVIDENCE
Experimental evidence is best regarded as a test of a causal hypothesis (see Table  5 ) than as a criterion for causal inference. In the early genetic linkage analysis studies, results were corroborated by cytogenetic or somatic cell hybrid studies in order to yield robust conclusions that could be used to direct clinical genetics risk estimations. The limitations of the utility of epidemiological evidence alone in determining causality are illustrated in the above discussion. This highlights the need to integrate epidemiological and statistical data with biological data in order to build a more robust framework for interpretation. A general framework for synthesising epidemiological and experimental data is illustrated in Figure 1 . Genetic variants showing positive associations with disease or disease traits that appear to be causal should be examined further in functional studies in knock-out animals or cell lines or in gene expression or enzyme activity studies, as appropriate. The discovery of the role of the mismatch repair genes in a subset of early onset colorectal cancer followed this model (Figure 2 ).
ALTERNATIVE APPROACHES TO USE OF ABOVE CRITERIA IN INTERPRETATION OF GENETIC ASSOCIATION STUDIES
The traditional epidemiological approach described above is one of assessing the validity of the association (by considering chance, bias and confounding; Table 2 ) and then applying inductive inference. This assesses the extent to which the data support an interpretation (or hypothesis) that the exposure or genetic variant under study is a cause of the disease (Table  3 ). An objective assessment is made of each of the above criteria leading to a judgement as to whether the weight of the evidence is in favour with this interpretation. This approach, however, is greatly compromised by the problems in interpretation highlighted above. An alternative and preferred approach is as a deductive test of causal hypotheses. A list of competing explanations (or hypotheses) for the association is set out. It is assumed by deduction that one of these is correct.
The competing explanations are then tested against the observed data. If only one remains unrefuted then it is considered to be correct. This is similar to an outbreak investigation in which possible exposures that may have caused the outbreak are eliminated one by one (eliminative induction). 38 An illustration of this approach is given in Table 5 . This deductive approach has a more secure basis in logic. 38 not been feasible in past epidemiological studies. This has placed severe limits on the approach to interpretation based on inference. The design of experimental studies (such as functional studies of genetic variants) is now increasingly possible in genetic epidemiology ( Figure 2 ). This should be seen as an essential step in the interpretation of genetic association studies and should ideally be planned by multidisciplinary teams including epidemiologists and statisticians together with geneticists and biologists. The expense of these studies is likely to be offset by the savings resulting from fewer research groups pursuing false positive associations.
CONCLUSIONS
The failure of the majority of reported genetic associations to lead to new insights into complex disease or drug response mechanisms challenges the perceived utility of this approach for the identification of genetic variants underlying common complex disease or responsiveness or adverse reaction to drugs. Closer attention to study design and use of bioinformatics data to inform data analysis (through empirical Bayes adjustments) has the potential to limit the rate of false positive reports. Suggestions that comparisons of groups of individuals defined by genotype in a genetic association study are equivalent to randomised comparison (due to ''Mendelian randomisation'') and thus not be susceptible to bias and most confounding effects are potentially important but need to be demonstrated empirically. 10 If the results of genetic association studies are to provide a useful guide to direct further research then an appropriate framework is required to assess whether genetic variants showing an (apparently valid) association with disease truly alter susceptibility to disease or response to drugs. Ideally, knowledge of genetic variability should inform study design and interpretation and this is likely to evolve as the Human Genome Diversity Project matures. Bioinformatics strategies should improve our ability to utilise biological knowledge to Genetic association studies in complex disease H Campbell and I Rudan direct epidemiological studies and inform interpretation of results. This will build a more scientific, evidence-based approach to the consideration of biological plausibility than the current unstructured and unhelpful approach and will result in this criterion becoming more useful in future. Consistency of association across studies is a useful indicator of causal association, when present. However, problems in interpreting failure to replicate findings limits the utility of this criterion and argues in favour of investment in large, integrated study designs that can perform internal checks in a single population. The difficulties in replicating associations in special populations or with rare variants should be recognised if important population-specific effects (which may give unique insights into molecular processes relevant to disease in all populations) are not to be discarded. Furthermore, meta-analyses to determine a summary measure of association across different populations may underestimate the effect of variants in specific populations. Strength of association remains a useful indicator of causal association but over-estimates due to bias are frequent. A deductive framework based on testing competing Select appropriate study population to answer study hypothesis (family-based study F multiplex family or affected family members; population-based study; special population F isolate or admixed; twins)
Adopt appropriate study design and procedures to limit bias and confounding
Recruit sufficiently large sample to ensure adequate power to detect modest association with genetic variant and to permit replication of finding within an independent subset of the data Select variants that are most likely to have functional effects in important biological pathways for investigation Select variants identified as positional or functional candidates from prior biological research (see Figure 1 ) for investigation Look for confirmatory evidence from gene expression studies (high levels of gene expression in tissues known to be affected by disease supports role in disease susceptibility)
causal hypotheses and involving both epidemiological and experimental data (for example from animal models or from gene expression or functional studies) is proposed. This review seeks to highlight the need for improved strategies for the interpretation of genetic association studies. In particular, the development and support of multidisciplinary groups with expertise in bioinformatics, (genetic) epidemiology/statistics and experimental biology is important for the future success of this field. Moving towards this model in which epidemiological and experimental biological data are synthesised together (Tables 4-6, Figure 1 ) will require recognition in the policies of research funding agencies and research funding to be redirected. 54 Current proposals to move away from a hypothesis testing paradigm of investigation to one of highthroughput (functional) genomics 55, 56 in which very large numbers of variants are related to a wide range of phenotypes underlines the need for an international consensus on a framework for the interpretation of genetic association studies and for the issues raised in this review to inform the design of these studies.
